Reports that US Food and Drug Administration’s Center for Biologic Evaluation and Research Director Peter Marks is assuming leadership of Pfizer Inc./BioNTech SE’s COVID-19 biologics license application raises some potential red flags the agency should be sure to handle carefully.
“I think it's great to have the center director engaged
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?